scispace - formally typeset
F

Fabrizio Salvi

Researcher at University of Bologna

Publications -  221
Citations -  14278

Fabrizio Salvi is an academic researcher from University of Bologna. The author has contributed to research in topics: Transthyretin & Chronic cerebrospinal venous insufficiency. The author has an hindex of 56, co-authored 213 publications receiving 12721 citations. Previous affiliations of Fabrizio Salvi include Academy for Urban School Leadership & University of Ferrara.

Papers
More filters
Journal ArticleDOI

Ultrastructure of internal jugular vein defective valves

TL;DR: Although the lack of endothelial cells in the internal jugular vein intraluminal obstacles is a further abnormality found in course of chronic cerebrospinal venous insufficiency, this investigation cannot clarify whether this finding is primary or caused by progressive loss of endothelium in relation to altered haemodynamic forces and/or to a past post-thrombotic/inflammatory remodelling.
Journal ArticleDOI

Genotypic and phenotypic correlation in an Italian population of hereditary amyloidosis TTR-related (HA-TTR): clinical and neurophysiological aids to diagnosis and some reflections on misdiagnosis.

TL;DR: Genetic screening of HA-TTR could be worthwhile in any idiopathic progressive axonal peripheral neuropathy as well as in drug resistant demyelinating sensory-motor neuropathy or in pure motor neuropathy, when multi-organ involvement is present.
Journal ArticleDOI

Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study.

TL;DR: In this paper, the authors evaluated the clinical utility of plasma (p) vs. CSF (c) NfL for distinguishing patients with Amyotrophic Lateral Sclerosis (ALS) from ALS mimics.
Journal ArticleDOI

Radiotherapy in Italy for non-small cell lung cancer: patterns of care survey.

TL;DR: It could be postulated that there is an urgent need for groups that collaborate with the other societies involved in the treatment of non-small cell lung cancer in order to offer the best therapy to the authors' patients.